Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization

  1. Harihar Basnet
  2. Lin Tian
  3. Karuna Ganesh
  4. Yun-Han Huang
  5. Danilo G Macalinao
  6. Edi Brogi
  7. Lydia Finley
  8. Joan Massagué  Is a corresponding author
  1. Memorial Sloan-Kettering Cancer Center, United States

Abstract

Metastasis-initiating cells dynamically adapt to the distinct microenvironments of different organs, but these early adaptations are poorly understood due to the limited sensitivity of in situ transcriptomics. We developed fluorouracil-labeled RNA sequencing (Flura-seq) for in situ analysis with high sensitivity. Flura-seq utilizes cytosine deaminase (CD) to convert fluorocytosine to fluorouracil, metabolically labeling nascent RNA in rare cell populations in situ for purification and sequencing. Flura-seq revealed hundreds of unique, dynamic organ-specific gene signatures depending on the microenvironment in mouse xenograft breast cancer micrometastases. Specifically, the mitochondrial electron transport Complex I, oxidative stress and counteracting antioxidant programs were induced in pulmonary micrometastases, compared to mammary tumors or brain micrometastases. We confirmed lung metastasis-specific increase in oxidative stress and upregulation of antioxidants in clinical samples, thus validating Flura-seq's utility in identifying clinically actionable microenvironmental adaptations in early metastasis. The sensitivity, robustness and economy of Flura-seq are broadly applicable beyond cancer research.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE93605 and GSE118937.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Harihar Basnet

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    Harihar Basnet, Has filed for patent for Flura-seq method (PCT/US18/22092).
  2. Lin Tian

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  3. Karuna Ganesh

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  4. Yun-Han Huang

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  5. Danilo G Macalinao

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  6. Edi Brogi

    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  7. Lydia Finley

    Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  8. Joan Massagué

    Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, United States
    For correspondence
    j-massague@ski.mskcc.org
    Competing interests
    Joan Massagué, Reviewing editor, eLife. Has filed for patent for Flura-seq method (PCT/US18/22092). Serves in the scientific advisory board and owns company stock in Scholar Rock.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9324-8408

Funding

National Institutes of Health (P01-CA094060)

  • Joan Massagué

Damon Runyon Cancer Research Foundation (DR-12998)

  • Harihar Basnet

Department of Defense (W81XWH-12-0074)

  • Joan Massagué

National Institutes of Health (T32-CA009207)

  • Karuna Ganesh

National Institutes of Health (T32-GM07739)

  • Yun-Han Huang

National Institutes of Health (K08-CA230213)

  • Karuna Ganesh

National Institutes of Health (F30-CA203238)

  • Yun-Han Huang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Mouse experiments were performed following the protocols approved by the MSKCC Institutional Animal Care and Use Committee (IACUC) (#99-09-032).

Reviewing Editor

  1. Matthew G Vander Heiden, Massachusetts Institute of Technology, United States

Publication history

  1. Received: November 14, 2018
  2. Accepted: March 6, 2019
  3. Accepted Manuscript published: March 26, 2019 (version 1)
  4. Version of Record published: March 29, 2019 (version 2)

Copyright

© 2019, Basnet et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,224
    Page views
  • 768
    Downloads
  • 35
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Harihar Basnet
  2. Lin Tian
  3. Karuna Ganesh
  4. Yun-Han Huang
  5. Danilo G Macalinao
  6. Edi Brogi
  7. Lydia Finley
  8. Joan Massagué
(2019)
Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization
eLife 8:e43627.
https://doi.org/10.7554/eLife.43627

Further reading

    1. Cancer Biology
    2. Cell Biology
    Katarzyna Bogucka-Janczi, Gregory Harms ... Krishnaraj Rajalingam
    Research Advance Updated

    The actin cytoskeleton is tightly controlled by RhoGTPases, actin binding-proteins and nucleation-promoting factors to perform fundamental cellular functions. We have previously shown that ERK3, an atypical MAPK, controls IL-8 production and chemotaxis (Bogueka et al., 2020). Here, we show in human cells that ERK3 directly acts as a guanine nucleotide exchange factor for CDC42 and phosphorylates the ARP3 subunit of the ARP2/3 complex at S418 to promote filopodia formation and actin polymerization, respectively. Consistently, depletion of ERK3 prevented both basal and EGF-dependent RAC1 and CDC42 activation, maintenance of F-actin content, filopodia formation, and epithelial cell migration. Further, ERK3 protein bound directly to the purified ARP2/3 complex and augmented polymerization of actin in vitro. ERK3 kinase activity was required for the formation of actin-rich protrusions in mammalian cells. These findings unveil a fundamentally unique pathway employed by cells to control actin-dependent cellular functions.

    1. Cancer Biology
    2. Cell Biology
    Julieta Martino, Sebastián Omar Siri ... Vanesa Gottifredi
    Research Article Updated

    The trapping of Poly-ADP-ribose polymerase (PARP) on DNA caused by PARP inhibitors (PARPi) triggers acute DNA replication stress and synthetic lethality (SL) in BRCA2-deficient cells. Hence, DNA damage is accepted as a prerequisite for SL in BRCA2-deficient cells. In contrast, here we show that inhibiting ROCK in BRCA2-deficient cells triggers SL independently from acute replication stress. Such SL is preceded by polyploidy and binucleation resulting from cytokinesis failure. Such initial mitosis abnormalities are followed by other M phase defects, including anaphase bridges and abnormal mitotic figures associated with multipolar spindles, supernumerary centrosomes and multinucleation. SL was also triggered by inhibiting Citron Rho-interacting kinase, another enzyme that, similarly to ROCK, regulates cytokinesis. Together, these observations demonstrate that cytokinesis failure triggers mitotic abnormalities and SL in BRCA2-deficient cells. Furthermore, the prevention of mitotic entry by depletion of Early mitotic inhibitor 1 (EMI1) augmented the survival of BRCA2-deficient cells treated with ROCK inhibitors, thus reinforcing the association between M phase and cell death in BRCA2-deficient cells. This novel SL differs from the one triggered by PARPi and uncovers mitosis as an Achilles heel of BRCA2-deficient cells.